NYSE:CBM - Cambrex Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$47.80 -0.15 (-0.31 %)
(As of 05/24/2018 02:23 AM ET)
Previous Close$47.95
Today's Range$47.70 - $48.55
52-Week Range$42.55 - $62.30
Volume282,500 shs
Average Volume312,320 shs
Market Capitalization$1.58 billion
P/E Ratio15.08
Dividend YieldN/A
Beta2.34

About Cambrex (NYSE:CBM)

Cambrex logoCambrex Corporation, a life sciences company, provides various products and services for the development and commercialization of new and generic therapeutics worldwide. Its products comprise active pharmaceutical ingredients and pharmaceutical intermediates that are used in the production of prescription and over-the-counter drug products, as well as other fine chemicals. The company serves generic drug companies; and companies that discover and commercialize small molecule human therapeutics. The company sells its products directly, as well as through independent agents. Cambrex Corporation was founded in 1981 and is headquartered in East Rutherford, New Jersey.

Receive CBM News and Ratings via Email

Sign-up to receive the latest news and ratings for CBM and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryLife Sciences Tools & Services
SectorMedical
SymbolNYSE:CBM
CUSIP13201110
Phone201-804-3000

Debt

Debt-to-Equity RatioN/A
Current Ratio5.04
Quick Ratio3.90

Price-To-Earnings

Trailing P/E Ratio15.08
Forward P/E Ratio17.51
P/E Growth1.17

Sales & Book Value

Annual Sales$534.46 million
Price / Sales2.95
Cash Flow$4.2077 per share
Price / Cash11.36
Book Value$17.98 per share
Price / Book2.66

Profitability

EPS (Most Recent Fiscal Year)$3.17
Net Income$102.45 million
Net Margins18.69%
Return on Equity21.00%
Return on Assets15.20%

Miscellaneous

Employees1,228
Outstanding Shares32,960,000

Cambrex (NYSE:CBM) Frequently Asked Questions

What is Cambrex's stock symbol?

Cambrex trades on the New York Stock Exchange (NYSE) under the ticker symbol "CBM."

How were Cambrex's earnings last quarter?

Cambrex Co. (NYSE:CBM) announced its earnings results on Thursday, May, 3rd. The biotechnology company reported $0.72 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.50 by $0.22. The biotechnology company earned $141.10 million during the quarter, compared to analyst estimates of $104.44 million. Cambrex had a net margin of 18.69% and a return on equity of 21.00%. The firm's quarterly revenue was up 34.4% compared to the same quarter last year. During the same period in the previous year, the business earned $0.68 earnings per share. View Cambrex's Earnings History.

When is Cambrex's next earnings date?

Cambrex is scheduled to release their next quarterly earnings announcement on Friday, August, 3rd 2018. View Earnings Estimates for Cambrex.

What guidance has Cambrex issued on next quarter's earnings?

Cambrex updated its FY18 earnings guidance on Thursday, May, 3rd. The company provided earnings per share guidance of $2.80 to $3.03 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $2.90.

What price target have analysts set for CBM?

3 brokers have issued twelve-month price objectives for Cambrex's stock. Their predictions range from $60.00 to $60.00. On average, they anticipate Cambrex's stock price to reach $60.00 in the next twelve months. View Analyst Ratings for Cambrex.

Who are some of Cambrex's key competitors?

Who are Cambrex's key executives?

Cambrex's management team includes the folowing people:
  • Mr. Steven M. Klosk, Pres, CEO & Director (Age 61)
  • Mr. Tom G. Vadaketh, Exec. VP & CFO (Age 55)
  • Mr. Shawn P. Cavanagh, Exec. VP & COO (Age 52)
  • Ms. Samantha M. Hanley, VP, Gen. Counsel & Corp. Sec. (Age 40)
  • Mr. Gregory P. Sargen, Exec. VP of Corp. Devel. & Strategy (Age 52)

Has Cambrex been receiving favorable news coverage?

Media headlines about CBM stock have trended positive on Thursday, according to Accern Sentiment. Accern rates the sentiment of media coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Cambrex earned a news impact score of 0.29 on Accern's scale. They also assigned news coverage about the biotechnology company an impact score of 46.08 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the near term.

Who are Cambrex's major shareholders?

Cambrex's stock is owned by many different of retail and institutional investors. Top institutional investors include BlackRock Inc. (12.90%), Dimensional Fund Advisors LP (4.27%), Boston Partners (2.06%), Northern Trust Corp (1.76%), Fiera Capital Corp (1.32%) and Neumeier Poma Investment Counsel LLC (1.19%). Company insiders that own Cambrex stock include Gregory Sargen, Leon J Hendrix Jr, Samantha Hanley, Shawn Cavanagh, Steven M Klosk and William B Korb. View Institutional Ownership Trends for Cambrex.

Which major investors are selling Cambrex stock?

CBM stock was sold by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN, Penn Capital Management Co. Inc., RMB Capital Management LLC, New York State Common Retirement Fund, Boston Partners, Nuveen Asset Management LLC, Comerica Bank and JW Asset Management LLC. Company insiders that have sold Cambrex company stock in the last year include Gregory Sargen, Leon J Hendrix Jr, Samantha Hanley, Shawn Cavanagh and Steven M Klosk. View Insider Buying and Selling for Cambrex.

Which major investors are buying Cambrex stock?

CBM stock was purchased by a variety of institutional investors in the last quarter, including Lord Abbett & CO. LLC, Loomis Sayles & Co. L P, Heartland Advisors Inc., Sei Investments Co., GW&K Investment Management LLC, BlackRock Inc., Carillon Tower Advisers Inc. and Point72 Asset Management L.P.. View Insider Buying and Selling for Cambrex.

How do I buy shares of Cambrex?

Shares of CBM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Cambrex's stock price today?

One share of CBM stock can currently be purchased for approximately $47.80.

How big of a company is Cambrex?

Cambrex has a market capitalization of $1.58 billion and generates $534.46 million in revenue each year. The biotechnology company earns $102.45 million in net income (profit) each year or $3.17 on an earnings per share basis. Cambrex employs 1,228 workers across the globe.

How can I contact Cambrex?

Cambrex's mailing address is ONE MEADOWLANDS PLZ, EAST RUTHERFORD NJ, 07073. The biotechnology company can be reached via phone at 201-804-3000 or via email at [email protected]


MarketBeat Community Rating for Cambrex (CBM)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  164 (Vote Outperform)
Underperform Votes:  147 (Vote Underperform)
Total Votes:  311
MarketBeat's community ratings are surveys of what our community members think about Cambrex and other stocks. Vote "Outperform" if you believe CBM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CBM will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Cambrex (NYSE:CBM) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
3 Wall Street analysts have issued ratings and price targets for Cambrex in the last 12 months. Their average twelve-month price target is $60.00, suggesting that the stock has a possible upside of 25.52%. The high price target for CBM is $60.00 and the low price target for CBM is $60.00. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.672.672.673.00
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $60.00$60.00$60.00$62.3333
Price Target Upside: 25.52% upside9.19% upside9.19% upside37.91% upside

Cambrex (NYSE:CBM) Consensus Price Target History

Price Target History for Cambrex (NYSE:CBM)

Cambrex (NYSE:CBM) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/14/2018Longbow ResearchDowngradeBuy ➝ NeutralMediumView Rating Details
1/16/2018William BlairInitiated CoverageOutperform ➝ OutperformHighView Rating Details
10/31/2017Craig HallumReiterated RatingBuy$70.00 ➝ $60.00N/AView Rating Details
2/6/2017StephensSet Price TargetBuy$61.00N/AView Rating Details
1/17/2017First AnalysisBoost Price TargetOverweight$54.00 ➝ $66.00N/AView Rating Details
(Data available from 5/24/2016 forward)

Earnings

Cambrex (NYSE:CBM) Earnings History and Estimates Chart

Earnings by Quarter for Cambrex (NYSE:CBM)

Cambrex (NYSE:CBM) Earnings Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181$0.47$0.47$0.47
Q2 20181$0.74$0.74$0.74
Q3 20181$0.57$0.57$0.57

Cambrex (NYSE CBM) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/2/2018$0.69N/AView Earnings Details
5/3/2018Q1 2018$0.50$0.72$104.44 million$141.10 millionViewN/AView Earnings Details
2/8/2018Q4 2017$1.10$1.27$181.39 million$182.28 millionViewN/AView Earnings Details
11/7/2017Q3 2017$0.47$0.55$108.44 million$112.60 millionViewN/AView Earnings Details
8/4/2017Q2 2017$0.76$0.76$136.82 million$134.55 millionViewN/AView Earnings Details
5/4/2017Q1 2017$0.51$0.68$99.05 million$105.01 millionViewListenView Earnings Details
2/3/2017Q416$1.05$1.23$174.53 million$178.70 millionViewListenView Earnings Details
11/4/2016Q3$0.41$0.47$96.07 million$99.90 millionViewListenView Earnings Details
7/28/2016Q216$0.59$0.68$114.85 million$118.22 millionViewListenView Earnings Details
4/29/2016Q116$0.34$0.50$83.61 million$94.74 millionViewListenView Earnings Details
2/9/2016Q4$0.83$0.53$152.94 million$156.90 millionViewListenView Earnings Details
11/3/2015Q3$0.38$0.40$101.09 million$92.97 millionViewListenView Earnings Details
7/30/2015Q215$0.44$0.63$110.03 million$106.40 millionViewListenView Earnings Details
5/1/2015Q115$0.23$0.29$76.01 million$78.20 millionViewListenView Earnings Details
2/6/2015Q414$0.50$0.60$117.90 million$128.80 millionViewListenView Earnings Details
10/30/2014Q314$0.29$0.28$94.25 million$81.10 millionViewListenView Earnings Details
8/12/2014$0.21$0.32ViewN/AView Earnings Details
8/1/2014Q214$0.28$0.32$92.70 million$98.00 millionViewListenView Earnings Details
5/2/2014Q114$0.23$0.05$79.40 million$66.20 millionViewListenView Earnings Details
2/11/2014Q4$0.30$0.30$95.25 million$103.00 millionViewListenView Earnings Details
11/1/2013Q313$0.21$0.20$83.60 million$78.00 millionViewListenView Earnings Details
8/1/2013Q2 2013$0.26$0.10$73.70 million$61.60 millionViewListenView Earnings Details
5/3/2013Q1 2013$0.22$0.36$76.15 million$74.58 millionViewListenView Earnings Details
2/6/2013Q4 2012$0.13$0.26$68.30 million$69.93 millionViewListenView Earnings Details
11/5/2012Q312$0.12$0.07$61.00 million$59.21 millionViewN/AView Earnings Details
8/1/2012$0.21$0.33ViewN/AView Earnings Details
5/3/2012$0.14$0.24ViewN/AView Earnings Details
2/6/2012$0.12$0.10ViewN/AView Earnings Details
11/3/2011$0.07$0.10ViewN/AView Earnings Details
8/2/2011$0.13$0.16ViewN/AView Earnings Details
5/5/2011$0.08$0.10ViewN/AView Earnings Details
2/10/2011$0.10$0.16ViewN/AView Earnings Details
11/3/2010Q3 2010$0.09$0.02ViewN/AView Earnings Details
8/3/2010Q2 2010$0.11$0.12ViewN/AView Earnings Details
5/4/2010Q1 2010$0.11$0.06ViewN/AView Earnings Details
2/10/2010Q4 2009$0.05($0.09)ViewN/AView Earnings Details
11/3/2009Q3 2009$0.05$0.10ViewN/AView Earnings Details
8/4/2009Q2 2009$0.10$0.19ViewN/AView Earnings Details
5/5/2009Q1 2009$0.09$0.16ViewN/AView Earnings Details
2/11/2009Q4 2008$0.09$0.05ViewN/AView Earnings Details
11/4/2008Q3 2008$0.05$0.10ViewN/AView Earnings Details
8/5/2008Q2 2008$0.12$0.08ViewN/AView Earnings Details
5/1/2008Q1 2008$0.14$0.16ViewN/AView Earnings Details
2/14/2008Q4 2007$0.13$0.11ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Cambrex (NYSE:CBM) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Cambrex (NYSE CBM) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 2.42%
Insider Trading History for Cambrex (NYSE:CBM)
Institutional Ownership by Quarter for Cambrex (NYSE:CBM)

Cambrex (NYSE CBM) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/8/2018Gregory SargenEVPSell67,500$49.48$3,339,900.00View SEC Filing  
5/8/2018Shawn CavanaghCOOSell40,000$49.69$1,987,600.00View SEC Filing  
10/2/2017Steven M KloskCEOSell4,000$54.96$219,840.0087,328View SEC Filing  
9/1/2017Steven M KloskCEOSell12,000$51.53$618,360.0095,328View SEC Filing  
8/1/2017Steven M KloskCEOSell12,000$61.39$736,680.0095,328View SEC Filing  
7/3/2017Steven M KloskCEOSell12,000$59.66$715,920.0095,328View SEC Filing  
6/12/2017Samantha HanleyVPSell14,000$57.56$805,840.001,500View SEC Filing  
6/6/2017Leon J Hendrix JrDirectorSell20,656$55.95$1,155,703.2074,662View SEC Filing  
6/1/2017Steven M KloskCEOSell12,000$54.19$650,280.0095,328View SEC Filing  
5/1/2017Steven M KloskCEOSell12,000$58.20$698,400.0095,328View SEC Filing  
4/3/2017Steven M KloskCEOSell12,000$54.58$654,960.0095,328View SEC Filing  
3/1/2017Steven M KloskCEOSell12,000$56.70$680,400.0095,328View SEC Filing  
2/27/2017Shawn CavanaghCOOSell19,620$55.95$1,097,739.0017,658View SEC Filing  
2/16/2017Steven M KloskCEOSell23,822$52.50$1,250,655.0094,241View SEC Filing  
2/13/2017Steven M KloskCEOSell63,178$52.55$3,320,003.90109,062View SEC Filing  
2/7/2017Gregory SargenEVPSell30,000$54.88$1,646,400.0050,000View SEC Filing  
2/7/2017Shawn CavanaghCOOSell20,380$55.12$1,123,345.6057,658View SEC Filing  
12/14/2016Shawn CavanaghCOOSell30,000$53.58$1,607,400.0027,658View SEC Filing  
11/11/2016Gregory SargenInsiderSell22,500$52.02$1,170,450.0027,500View SEC Filing  
7/11/2016William B KorbDirectorSell3,420$55.00$188,100.0023,982View SEC Filing  
6/8/2016William B KorbDirectorSell4,142$52.47$217,330.7424,704View SEC Filing  
6/1/2016William B KorbDirectorSell8,000$51.06$408,480.0025,304View SEC Filing  
5/9/2016Steven M KloskCEOSell14,005$49.00$686,245.00147,333View SEC Filing  
5/5/2016Steven M KloskCEOSell16,430$49.13$807,205.90136,828View SEC Filing  
5/3/2016William B KorbDirectorSell8,000$49.09$392,720.0032,562View SEC Filing  
3/16/2016Steven M KloskCEOSell19,565$41.00$802,165.00152,893View SEC Filing  
3/15/2016Louis J GrabowskyDirectorBuy750$40.10$30,075.00928View SEC Filing  
3/10/2016William B KorbDirectorSell8,000$41.38$331,040.0032,562View SEC Filing  
2/11/2016Gregory SargenCFOSell13,622$36.16$492,571.5246,697View SEC Filing  
2/11/2016Shawn CavanaghCOOSell18,342$36.13$662,696.4617,658View SEC Filing  
2/11/2016Steven M. KloskCEOSell39,542$36.20$1,431,420.40133,328View SEC Filing  
12/15/2015Leon J. Hendrix, Jr.DirectorSell7,000$51.34$359,380.0071,211View SEC Filing  
12/11/2015Peter G. TombrosDirectorSell31,236$51.37$1,604,593.3221,520View SEC Filing  
11/30/2015Ilan KaufthalDirectorSell52,315$54.32$2,841,750.8060,000View SEC Filing  
11/13/2015Gregory SargenCFOSell28,750$49.14$1,412,775.0033,319View SEC Filing  
11/6/2015Samantha HanleyVPSell15,000$52.03$780,450.00View SEC Filing  
8/27/2015William B. KorbDirectorSell3,600$48.00$172,800.0046,562View SEC Filing  
5/21/2015Ilan KaufthalDirectorSell50,000$41.31$2,065,500.00View SEC Filing  
5/11/2015Gregory SargenCFOSell25,000$38.44$961,000.00View SEC Filing  
2/12/2015Aldo MagniniDirectorSell7,500$32.75$245,625.00View SEC Filing  
2/12/2015Gregory SargenCFOSell25,000$32.64$816,000.00View SEC Filing  
2/10/2015Steven M KloskCEOSell45,000$30.32$1,364,400.00View SEC Filing  
9/11/2014Shawn CavanaghCOOSell56,251$22.56$1,269,022.56View SEC Filing  
9/3/2014Steven M KloskCEOSell126,257$22.01$2,778,916.57View SEC Filing  
9/2/2014William M HaskelSVPSell9,400$21.94$206,236.00View SEC Filing  
8/19/2014Steven M KloskCEOSell4,702$22.00$103,444.00View SEC Filing  
8/7/2014Steven M KloskCEOSell1,200$22.52$27,024.00View SEC Filing  
8/7/2014William M HaskelSVPSell28,100$22.50$632,250.00View SEC Filing  
8/5/2014Gregory SargenCFOSell50,000$22.34$1,117,000.00View SEC Filing  
2/28/2014Leon Hendrix, Jr.DirectorSell23,000$20.09$462,070.0092,993View SEC Filing  
2/20/2014Aldo MagniniDirectorSell6,000$22.10$132,600.00View SEC Filing  
12/5/2013Paolo RussoloInsiderSell35,000$18.40$644,000.0067,085View SEC Filing  
11/11/2013Gregory SargenCFOSell20,000$18.92$378,400.0033,319View SEC Filing  
11/11/2013John MillerDirectorSell2,000$19.21$38,420.0035,306View SEC Filing  
5/24/2013Paolo RussoloInsiderSell32,903$12.53$412,274.59View SEC Filing  
5/16/2013Leon J Hendrix JrDirectorSell1,120$13.40$15,008.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Cambrex (NYSE CBM) News Headlines

Source:
DateHeadline
Cambrex (CBM) Upgraded to Hold by Zacks Investment ResearchCambrex (CBM) Upgraded to Hold by Zacks Investment Research
www.americanbankingnews.com - May 16 at 8:19 PM
Cambrex Completes Pilot Plant Expansion at its High Point, NC FacilityCambrex Completes Pilot Plant Expansion at its High Point, NC Facility
finance.yahoo.com - May 15 at 9:26 AM
Cambrex (CBM) Downgraded to "Sell" at Zacks Investment ResearchCambrex (CBM) Downgraded to "Sell" at Zacks Investment Research
www.americanbankingnews.com - May 10 at 6:51 PM
Shawn Cavanagh Sells 40,000 Shares of Cambrex Co. (CBM) StockShawn Cavanagh Sells 40,000 Shares of Cambrex Co. (CBM) Stock
www.americanbankingnews.com - May 9 at 7:16 PM
Cambrex Co. (CBM) EVP Gregory Sargen Sells 67,500 SharesCambrex Co. (CBM) EVP Gregory Sargen Sells 67,500 Shares
www.americanbankingnews.com - May 9 at 7:15 PM
Cambrexs (CBM) CEO Steven Klosk on Q1 2018 Results - Earnings Call TranscriptCambrex's (CBM) CEO Steven Klosk on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 5 at 9:14 AM
Cambrex Co. (CBM) Expected to Post Quarterly Sales of $161.55 MillionCambrex Co. (CBM) Expected to Post Quarterly Sales of $161.55 Million
www.americanbankingnews.com - May 5 at 3:02 AM
Edited Transcript of CBM earnings conference call or presentation 3-May-18 12:30pm GMTEdited Transcript of CBM earnings conference call or presentation 3-May-18 12:30pm GMT
finance.yahoo.com - May 4 at 8:56 AM
Cambrex (CBM) Stock Rating Lowered by ValuEngineCambrex (CBM) Stock Rating Lowered by ValuEngine
www.americanbankingnews.com - May 3 at 11:47 PM
Cambrex (CBM) Releases  Earnings Results, Beats Estimates By $0.22 EPSCambrex (CBM) Releases Earnings Results, Beats Estimates By $0.22 EPS
www.americanbankingnews.com - May 3 at 9:38 PM
$0.52 Earnings Per Share Expected for Cambrex Co. (CBM) This Quarter$0.52 Earnings Per Share Expected for Cambrex Co. (CBM) This Quarter
www.americanbankingnews.com - May 3 at 8:33 PM
Cambrex: 1Q Earnings SnapshotCambrex: 1Q Earnings Snapshot
finance.yahoo.com - May 3 at 4:48 PM
Cambrex (CBM) Releases FY18 Earnings GuidanceCambrex (CBM) Releases FY18 Earnings Guidance
www.americanbankingnews.com - May 3 at 10:29 AM
Form 10-Q CAMBREX CORP For: Mar 31Form 10-Q CAMBREX CORP For: Mar 31
www.streetinsider.com - May 3 at 8:56 AM
Cambrex Reports First Quarter 2018 Financial ResultsCambrex Reports First Quarter 2018 Financial Results
finance.yahoo.com - May 3 at 8:56 AM
Cambrex Co. (CBM) Given Average Rating of "Hold" by BrokeragesCambrex Co. (CBM) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - May 3 at 1:54 AM
Form 4 CAMBREX CORP For: Apr 26 Filed by: Yanai ShlomoForm 4 CAMBREX CORP For: Apr 26 Filed by: Yanai Shlomo
www.streetinsider.com - May 1 at 9:03 AM
Investor Expectations to Drive Momentum within Blackbaud, Pieris Pharmaceuticals, Sarepta Therapeutics, Cambrex ...Investor Expectations to Drive Momentum within Blackbaud, Pieris Pharmaceuticals, Sarepta Therapeutics, Cambrex ...
globenewswire.com - April 27 at 9:27 AM
Cambrex to Announce First Quarter 2018 Financial Results on May 3, 2018Cambrex to Announce First Quarter 2018 Financial Results on May 3, 2018
finance.yahoo.com - April 26 at 4:48 PM
Cambrex (CBM) Scheduled to Post Quarterly Earnings on WednesdayCambrex (CBM) Scheduled to Post Quarterly Earnings on Wednesday
www.americanbankingnews.com - April 25 at 3:16 AM
Cambrex Completes New $3.2 Million Analytical Research & Development Laboratory at its High Point, NC FacilityCambrex Completes New $3.2 Million Analytical Research & Development Laboratory at its High Point, NC Facility
finance.yahoo.com - April 23 at 8:47 AM
Cambrex Corporation to Provide Additional Information Regarding its Environmental, Social and Governance PracticesCambrex Corporation to Provide Additional Information Regarding its Environmental, Social and Governance Practices
finance.yahoo.com - April 19 at 5:01 PM
vTv Therapeutics plans to keep its High Point headquarters despite building sale, clinical setbackvTv Therapeutics plans to keep its High Point headquarters despite building sale, clinical setback
www.bizjournals.com - April 18 at 9:01 AM
Cambrex Co. (CBM) Expected to Post Quarterly Sales of $110.80 MillionCambrex Co. (CBM) Expected to Post Quarterly Sales of $110.80 Million
www.americanbankingnews.com - April 18 at 3:04 AM
Cambrex Invests in New Continuous Flow Technology at its High Point, NC FacilityCambrex Invests in New Continuous Flow Technology at its High Point, NC Facility
finance.yahoo.com - April 17 at 9:18 AM
Cambrex Co. (CBM) Expected to Announce Earnings of $0.31 Per ShareCambrex Co. (CBM) Expected to Announce Earnings of $0.31 Per Share
www.americanbankingnews.com - April 16 at 1:12 PM
Cambrex, poised for another expansion, buys two properties for $10.2MCambrex, poised for another expansion, buys two properties for $10.2M
www.bizjournals.com - April 16 at 8:55 AM
Cambrex (CBM) Lifted to Hold at Zacks Investment ResearchCambrex (CBM) Lifted to Hold at Zacks Investment Research
www.americanbankingnews.com - April 11 at 6:43 PM
Cambrex (CBM) Upgraded to Buy at ValuEngineCambrex (CBM) Upgraded to Buy at ValuEngine
www.americanbankingnews.com - April 10 at 9:17 AM
Cambrex Co. (CBM) Receives Consensus Recommendation of "Hold" from BrokeragesCambrex Co. (CBM) Receives Consensus Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - April 8 at 1:30 AM
Cleantech Building Materials: Notice of AGMCleantech Building Materials: Notice of AGM
finance.yahoo.com - April 3 at 4:54 PM
Cambrex (CBM) Rating Reiterated by Craig HallumCambrex (CBM) Rating Reiterated by Craig Hallum
www.americanbankingnews.com - April 2 at 8:04 PM
Cambrex Co. (CBM) Expected to Announce Quarterly Sales of $110.80 MillionCambrex Co. (CBM) Expected to Announce Quarterly Sales of $110.80 Million
www.americanbankingnews.com - April 1 at 2:54 AM
Zacks: Brokerages Anticipate Cambrex Co. (CBM) Will Announce Earnings of $0.31 Per ShareZacks: Brokerages Anticipate Cambrex Co. (CBM) Will Announce Earnings of $0.31 Per Share
www.americanbankingnews.com - March 30 at 3:10 PM
Cleantech Building Materials: Annual Results to 31 December 2017Cleantech Building Materials: Annual Results to 31 December 2017
finance.yahoo.com - March 29 at 9:16 AM
Cambrex (CBM) Downgraded to Sell at Zacks Investment ResearchCambrex (CBM) Downgraded to Sell at Zacks Investment Research
www.americanbankingnews.com - March 20 at 8:16 PM
Cleantech Building Materials: Application to Wiener BörseCleantech Building Materials: Application to Wiener Börse
finance.yahoo.com - March 16 at 9:11 AM
Free Post Earnings Research Report: Cambrex Achieved Record Quarterly Revenue; EPS Climbed 4%Free Post Earnings Research Report: Cambrex Achieved Record Quarterly Revenue; EPS Climbed 4%
finance.yahoo.com - March 16 at 9:11 AM
Should Value Investors Pick Cambrex (CBM) Stock?Should Value Investors Pick Cambrex (CBM) Stock?
finance.yahoo.com - March 15 at 5:25 PM
$110.80 Million in Sales Expected for Cambrex Co. (CBM) This Quarter$110.80 Million in Sales Expected for Cambrex Co. (CBM) This Quarter
www.americanbankingnews.com - March 15 at 4:58 AM
Cambrex Co. (CBM) Given Consensus Rating of "Hold" by AnalystsCambrex Co. (CBM) Given Consensus Rating of "Hold" by Analysts
www.americanbankingnews.com - March 14 at 1:54 AM
Zacks: Analysts Anticipate Cambrex Co. (CBM) to Post $0.31 Earnings Per ShareZacks: Analysts Anticipate Cambrex Co. (CBM) to Post $0.31 Earnings Per Share
www.americanbankingnews.com - March 13 at 12:50 PM
Cambrex Co. (CBM) Holdings Trimmed by Ranger Investment Management L.P.Cambrex Co. (CBM) Holdings Trimmed by Ranger Investment Management L.P.
www.americanbankingnews.com - March 5 at 3:37 PM
Lazard Asset Management LLC Invests $22.20 Million in Cambrex Co. (CBM)Lazard Asset Management LLC Invests $22.20 Million in Cambrex Co. (CBM)
www.americanbankingnews.com - March 5 at 11:11 AM
Cambrex Co. (CBM) Shares Sold by Bank of New York Mellon CorpCambrex Co. (CBM) Shares Sold by Bank of New York Mellon Corp
www.americanbankingnews.com - March 5 at 5:00 AM
Cambrex Co. (CBM) Shares Sold by Kennedy Capital Management Inc.Cambrex Co. (CBM) Shares Sold by Kennedy Capital Management Inc.
www.americanbankingnews.com - March 3 at 3:30 PM
Royce & Associates LP Has $4.30 Million Holdings in Cambrex Co. (CBM)Royce & Associates LP Has $4.30 Million Holdings in Cambrex Co. (CBM)
www.americanbankingnews.com - March 3 at 9:12 AM
Cambrex Co. (CBM) Stake Lessened by King Luther Capital Management CorpCambrex Co. (CBM) Stake Lessened by King Luther Capital Management Corp
www.americanbankingnews.com - March 2 at 12:33 PM
AlphaOne Investment Services LLC Reduces Stake in Cambrex Co. (CBM)AlphaOne Investment Services LLC Reduces Stake in Cambrex Co. (CBM)
www.americanbankingnews.com - February 26 at 5:14 AM
Cambrex Co. (CBM) Shares Bought by Pinebridge Investments L.P.Cambrex Co. (CBM) Shares Bought by Pinebridge Investments L.P.
www.americanbankingnews.com - February 25 at 9:30 AM

SEC Filings

Cambrex (NYSE:CBM) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Cambrex (NYSE:CBM) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Cambrex (NYSE CBM) Stock Chart for Thursday, May, 24, 2018

Loading chart…

This page was last updated on 5/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.